The current therapeutic scenario for relapsed mantle cell lymphoma

Current Opinion in Oncology

Volumn 25, Issue 5, 2013, Pages 452-462

  Ferrero, Simone ^a,b   Dreyling, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Mantle cell lymphoma; New drugs; Refractory; Relapse; Therapy

Indexed keywords

ABEXINOSTAT; ABT 199; BENDAMUSTINE; BLINATUMOMAB; BORTEZOMIB; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; FLAVOPIRIDOL; FLUDARABINE; GEMCITABINE; IBRITUMOMAB TIUXETAN; IBRUTINIB; IDELALISIB; LENALIDOMIDE; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OFATUMUMAB; PALBOCICLIB; PREDNISONE; PROCARBAZINE; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; YTTRIUM 90; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; PROTEIN KINASE INHIBITOR;

ALLOTRANSPLANTATION; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CELL CYCLE; COMORBIDITY; FATIGUE; HUMAN; MANTLE CELL LYMPHOMA; MONOTHERAPY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; THROMBOCYTOPENIA; ALGORITHM; CLINICAL TRIAL (TOPIC); LYMPHOMA, MANTLE-CELL; MOLECULARLY TARGETED THERAPY; PROCEDURES; RECURRENT DISEASE;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOMA, MANTLE-CELL; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECURRENCE;

EID: 84883227790     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328363df0b     Document Type: Review

References (67)

1. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009; 27: 511-518; doi: 10.1200/JCO.2008.16.8435.
2. Peérez-Galán P, Dreyling M, Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26-38; doi: 10.1182/blood-2010-04-189977.
3. Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012; 119: 1963-1971; doi: 10.1182/blood-2011-11-391474.
4. Iqbal J, Shen Y, Liu Y, et al. Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood 2012; 119: 4939-4948; doi: 10.1182/blood-2011-07-370122.
5. Choi YJ, Li X, Hydbring P, et al. The requirement for cyclin D function in tumor maintenance. Cancer Cell 2012; 22: 438-451; doi: 10.1016/j.ccr.2012. 09.015.
6. Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693; doi: 10.1182/blood-2008-03-147025.
7. Hermine O, Hoster E, Walewski J, et al. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Increases Overall Survival When Compared to 6 Courses of CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT in Mantle Cell Lymphoma: Final Analysis of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood (ASH Annual Meeting Abstracts) 2012; 120: 151.
8. Le Gouill S, Callanan M, Macintyre E, et al. Clinical, Metabolic and Molecular Responses After 4 Courses of R-DHAP and After Autologous Stem Cell Transplantation for Untreated Mantle Cell Lymphoma Patients Included in the LyMa Trial, a Lysa Study. Blood (ASH Annual Meeting Abstracts) 2012; 120: 152.
9. Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013; 24: 857-877; doi: 10.1093/annonc/mds643. Updated guidelines for diagnosis, prognostication and treatment of MCL.
10. Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200-208; doi: 10.1111/j.1365-2141.2010.08228.x.
11. Merli F, Luminari S, Ilariucci F, et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156: 346-353; doi: 10.1111/j.1365-2141. 2011.08958.x.
12. Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531; doi: 10. 1056/NEJMoa1200920.
13. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064-3071.
14. Rodríguez J, Gutierrez A, Palacios A, et al. Rituximab, gemcitabine and oxaliplatin: an effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 2007; 48: 2172-2178.
15. Witzig TE, Geyer SM, Kurtin PJ, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 2008; 49: 1074-1080; doi: 10.1080/10428190801993470.
16. Rummel MJ, Al-Batran SE, Kim SZ, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383-3389.
17. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 noninferiority trial. Lancet 2013. doi:pii: S0140-673661763-2. 10.1016/S0140-6736(12)61763-2.
18. Visco C, Finotto S, Zambello R, et al. Combination of Rituximab, Bendamustine, and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation. J Clin Oncol 2013. Although on a limited patients series, this phase I/II study addresses a highly promising therapeutic combination for relapsed MCL.
19. Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009; 113: 4144-4152; doi: 10.1182/blood-2008-10-184200.
20. Ruan J, Martin P, Coleman M, et al. Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma. Cancer 2010; 116: 2655-2664; doi: 10.1002/cncr.25055.
21. Coleman M, Ruan G, Elstrom RL, et al. Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen. Hematology 2012; 17 (Suppl 1):S90-S92; doi: 10.1179/ 102453312X13336169155970.
22. Goy A, Younes A, McLaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-675.
23. O'ConnorOA, Wright J, Moskowitz C, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-684.
24. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867-4874.
25. Goy A, Bernstein SH, Kahl BS, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009; 20: 520-525; doi: 10.1093/annonc/mdn656.
26. Baiocchi RA, Alinari L, Lustberg ME, et al. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma. Cancer 2011; 117: 2442-2451.
27. Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica 2011; 96: 1008-1014; doi: 10.3324/haematol.2011.041392.
28. Weigert O, Weidmann E, Mueck R, et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study. Leuk Lymphoma 2009; 50: 716-722; doi: 10.1080/10428190902856790.
29. Gerecitano J, Portlock C, Hamlin P, et al. Phase I trial of weekly and twiceweekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma. Clin Cancer Res 2011; 17: 2493-2501; doi: 10.1158/1078-0432.CCR-10-1498.
30. Friedberg JW, Vose JM, Kelly JL, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011; 117: 2807-2812; doi: 10.1182/blood-2010-11-314708.
31. Kouroukis CT, Fernandez LA, Crump M, et al. A phase II study of bortezomib and gemcitabine in relapsed mantle cell lymphoma from the National Cancer Institute of Canada Clinical Trials Group (IND 172). Leuk Lymphoma 2011; 52: 394-399; doi: 10.3109/10428194.2010.546015.
32. Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011; 29: 690-697; doi: 10.1200/JCO.2010.31.1142.
33. Houot R, Le Gouill S, Ojeda Uribe M, et al. Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: results of a phase II trial from the GOELAMS. Ann Oncol 2012; 23: 1555-1561; doi: 10.1093/annonc/mdr450.
34. Kahl BS, Li H, Smith MR, et al. Mature Results From ECOG Study E1405 - A Phase II Study of VcR-CVAD with Maintenance Rituximab for Previously Untreated Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 2012; 120: 153.
35. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 3822-3829; doi: 10.1200/JCO.2008.20.7977.
36. Ansell SM, Tang H, Kurtin PJ, et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12: 361-368. doi: 10.1016/S1470-2045(11)70062-6.
37. Hess G, Keller H, Atta J, et al. Temsirolimus in Combination with Bendamustine and Rituximab for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Report on An Ongoing Phase I/II Trial. Blood (ASH Annual Meeting Abstracts) 2011; 118: 2697.
38. Renner C, Zinzani PL, Gressin R, et al. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 2012; 97: 1085-1091; doi: 10.3324/haematol.2011.053173.
39. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008; 26: 4952-4957; doi: 10.1200/JCO.2007.15.3429.
40. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II trial of singleagent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627; doi: 10.1093/annonc/ mdq626.
41. Eve HE, Carey S, Richardson SJ, et al. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012; 159: 154-163; doi: 10.1111/bjh.12008.
42. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol 2012; 13: 716-723. doi: 10.1016/S1470-2045(12)70200-0. The combination of lenalidomide and rituximab in 44 patients achieved the highest response and survival rates published so far for relapsed/refractory MCL.
43. Zaja F, De Luca S, Vitolo U, et al. Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. Haematologica 2012; 97: 416-422; doi: 10.3324/haematol.2011. 051813.
44. Kaufmann H, Raderer M, Wöhrer S, et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004; 104: 2269-2271.
45. Harel S, Bachy E, Haioun C, et al. Efficacy and Safety of Thalidomide In Mantle Cell Lymphoma: Results of the French ATU Program. Blood (ASH Annual Meeting Abstracts) 2010; 116: 1794.
46. Wang M, Oki Y, Pro B, et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27: 5213-5218; doi: 10.1200/JCO.2009.21.8545.
47. Smith MR, Li H, Gordon L, et al. Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 2012; 30: 3119-3126; doi: 10.1200/JCO.2012.42.2444.
48. Beaven AW, Shea TC, Moore DT, et al. A phase I study evaluating ibritumomab tiuxetan (Zevalin1) in combination with bortezomib (Velcade1) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leuk Lymphoma 2012; 53: 254-258; doi: 10.3109/10428194.2011. 608445. Epub 2011 Sep 19.
49. Wang M, Rule SA, Martin P, et al. Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. Blood (ASH Annual Meeting Abstracts) 2012; 120: 904. Although this abstract shows only the interim results of a large international phase II trial on 110 refractory/relapsed MCL patients, the high efficacy and the excellent tolerability of this drug are impressive.
50. Dasmahapatra G, Patel H, Dent P, et al. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 2013; 161: 43-56; doi: 10.1111/bjh.12206.
51. Kahl B, Byrd JC, Flinn IW, et al. Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110{delta}, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma. Blood (ASH Annual Meeting Abstracts) 2010; 116: 1777.
52. Cartron G, Thieblemont C, Solal-Celigny P, et al. Promising Efficacy with the New Anti-CD20 Antibody GA101 In Heavily Pre-Treated NHL Patients - First Results From a Phase II Study In Patients with Relapsed/Refractory DLBCL and MCL. Blood (ASH Annual Meeting Abstracts) 2010; 116: 2878.
53. Magni M, Di Nicola M, Carlo-Stella C, et al. Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study. Blood (ASH Annual Meeting Abstracts) 2011; 118: 1647.
54. Vose JM, Loberiza FR, Bociek RG, et al. Phase I/II Trial of Ofatumumab/Lenalidamide for Patients with Relasped/Refractory B-Cell Non-Hodgkin Lymphoma: High Response Rate in Indolent Lymphoma. Blood (ASH Annual Meeting Abstracts) 2012; 120: 3692.
55. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008; 321: 974-977; doi: 10.1126/science.1158545.
56. Viardot A, Goebeler M, Scheele JS, et al. Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60mg/m2/d Is Tolerable and Highly Effective. Blood (ASH Annual Meeting Abstracts) 2010; 116: 2880.
57. Palanca-Wessels MC, Flinn IW, Sehn LH. e al. A Phase I Study of the Anti-CD79b Antibody-Drug Conjugate (ADC) DCDS4501A Targeting CD79b in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2012; 120: 56.
58. Lin TS, Blum KA, Fischer DB, et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010; 28: 418-423; doi: 10.1200/JCO.2009.24.1570.
59. Holkova B, Perkins EB, Ramakrishnan V, et al. Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms. Clin Cancer Res 2011; 17: 3388-3397; doi: 10.1158/1078-0432.CCR-10-2876.
60. Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 2012; 119: 4597-4607; doi: 10.1182/blood-2011-10-388298.
61. Davids MS, Roberts AW, Anderson MA, et al. The BCL-2-Specific BH3- Mimetic ABT-199 (GDC-0199) Is Active and Well Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study. Blood (ASH Annual Meeting Abstracts) 2012; 120: 304.
62. Evens AM, Vose JM, Harb W, et al. A Phase II Multicenter Study of the Histone Deacetylase Inhibitor (HDACi) Abexinostat (PCI-24781) in Relapsed/Refractory Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL). Blood (ASH Annual Meeting Abstracts) 2012; 120: 55.
63. Le Gouill S, Kröger N, Dhedin N, et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience. Ann Oncol 2012; 23: 2695-2703.
64. Hamadani M, Saber W, Ahn KW, et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2013; 19: 625-631; doi: 10.1016/j.bbmt.2013.01. 009. This large retrospective study of 202 patients with chemorefractory MCL receiving allogeneic transplantation indicates that durable remissions can be achieved at least in a fraction of these poor prognosis patients.
65. Bethge WA, von Harsdorf S, Bornhauser M, et al. Dose-escalated radioimmunotherapy as part of reduced intensity conditioning for allogeneic transplantation in patients with advanced high-grade non-Hodgkin lymphoma. Bone Marrow Transplant 2012; 47: 1397-1402; doi: 10.1038/bmt.2012.62.
66. Gopal AK, Guthrie KA, Rajendran J, et al. 90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma. Blood 2011; 118: 1132-1139; doi: 10.1182/blood-2010-12-324392.
67. Hoster E, Klapper W, Rosenwald A, et al. Cell Proliferation (Ki-67) As Prognostic Marker in Mantle Cell Lymphoma. Blood (ASH Annual Meeting Abstracts) 2012; 120: 2677.